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Abstract
Background—Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an
arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited
value.
Objective—We present a CPVT family in which marked post-pacing repolarization
abnormalities during EPS were the only consistent phenotypic manifestation of RyR2 mutation
carriers.
Methods—The study was prompted by the observation of transient marked QT prolongation
preceding initiation of ventricular fibrillation during atrial fibrillation in a boy with a family
history of sudden cardiac death (SCD). Family members underwent exercise and pharmacologic
ECG testing with epinephrine, adenosine and flecainide. Non-invasive clinical tests were normal
in 10 patients evaluated, except for both epinephrine and exercise-induced ventricular arrhythmias
in 1. EPS included bursts of ventricular pacing and programmed ventricular extrastimulation
reproducing short-long sequences. Genetic screening involved direct sequencing of genes involved
in LQTS as well as RyR2.
Results—Six patients demonstrated a marked increase in QT interval only in the first beat after
cessation of ventricular pacing and/or extrastimulation. All 6 patients were found to have a
heterozygous missense mutation (M4109R) in RyR2. Two of them, presenting with aborted SCD
also had a second missense mutation (I406T- RyR2). Four family members without RyR2
mutations did not display prominent post-pacing QT changes.
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Conclusions—M4109R- RyR2 is associated with a high incidence of SCD. The contribution of
I406T to the clinical phenotype is unclear. In contrast to exercise testing, marked post-pacing
repolarization changes in a single beat accurately predicted carriers of M4109R- RyR2 in this
family.
Keywords
sudden death; genetics; ion channels; electrophysiology
INTRODUCTION
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrhythmogenic
disease characterized by exercise- or stress-induced ventricular tachyarrhythmias, leading to
syncope or sudden cardiac death (SCD) (1). The latter could be the first manifestation in
some patients. Typically, CPVT patients have no evidence of structural heart disease. Their
resting ECG is usually normal with a normal QT interval, although some authors have
reported mild sinus bradycardia (2) and prominent U waves (2–4). Exercise testing is a very
useful diagnostic tool showing reproducible induction of various types of ventricular
arrhythmias ranging from premature ventricular contractions (PVC) and ventricular
bigeminy to a distinctive pattern of bidirectional as well as polymorphic ventricular
tachycardia (VT) (5–7). In contrast, electrophysiologic studies (EPS) have shown to be of
limited diagnostic value in CPVT, showing either no (8) or rare (5) inducibility of non-
sustained polymorphic VT.
CPVT is an inherited disease and disease-causing mutations in ryanodine receptor (RyR2) or
calsequestrin 2 genes (CASQ2) have been identified in 50–70% of the affected patients (9).
The RyR2 mutations are responsible for the autosomal dominant form of CPVT, while
CASQ2 mutations are rare and account for the recessive form (5, 10– 12). These mutations
lead to diastolic calcium leakage producing calcium overload in the cardiac myocyte, which
can result in triggered activity resulting from delayed after depolarizations (DADs) (13, 14).
Identification of affected family members is challenging as some patients do not exhibit
ventricular arrhythmias during non-invasive testing. Furthermore, genetic testing is not
always available and even when it is, mutations in the known genes associated with CPVT
are unidentifiable in some patients. We present a CPVT family in which marked post-pacing
repolarization abnormalities during EPS were the only consistent phenotypic manifestation
of RyR2 mutation carriers.
METHODS
Patients
The first family member who came to our attention (proband) was a previously healthy 31-
year old Sephardic Jew female (III-2 in pedigree; Fig. 1) with aborted SCD due to
ventricular fibrillation (VF). Her cardiac arrest occurred early in the morning at work.
Interrogation of two people who witnessed the cardiac arrest suggested that the patient was
under some stress before collapsing. She was married to her second cousin and was the
mother of 5 children aged 9–16 years. Her father and brother both died suddenly at ages 30
and 9, respectively (Fig. 1). Her initial evaluation showed no obvious heart disease as
attested by a normal echocardiogram and a normal resting ECG including heart rate ranging
from 75–100 beats/min and a normal QTc. Following her cardiac arrest, she survived in
vegetative state for 10 years during which she had recurrent episodes of VF. The trigger of
the VF episodes during hospitalization was fever (mainly urinary tract infections). A
combined therapy of amiodarone and quinidine given during a 2-year period was effective in
preventing the arrhythmic events without resulting in significant QT prolongation. One of
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her two sons (V-2 in pedigree; Fig 1) presented with a documented VF during emotional
stress at the age of 15. He was successfully resuscitated and was taken to a nearby hospital.
Upon admission he had another documented VF initiated by rapid atrial fibrillation (AF).
VF occurred after a marked QT prolongation following a short-long sequence during AF
(Fig. 2). Multiple ECGs in sinus rhythm obtained later repeatedly showed normal QT
values. He was subsequently treated with an automatic implantable cardioverter defibrillator
(ICD). One year later her 12-year old daughter (V-4 in pedigree; Fig 1) also experienced
cardiac arrest while startled during a walk. She had VF documentation from which she was
successfully resuscitated. Multiple ECGs in sinus rhythm obtained later also failed to show
any QT prolongation. She also received an ICD.
At the time of the proband's hospitalization following her initial cardiac arrest, her 30-year
old sister (III- 4 in pedigree; Fig 1), mother of 8 children aged 3–18 years was carefully
investigated. Except for mild exercise-induced ventricular arrhythmias, her cardiologic
work-up was negative, including normal QTc values; however due to the strong family
history of SCD, she received an ICD.
Study protocol
Following the cardiac arrest of proband's son and the observation of marked QT
prolongation preceding the VF initiation during AF in the absence of obvious (long QT
syndrome) LQTS, the family members were invited to perform a comprehensive evaluation
including echocardiogram, a resting 12- lead ECG, a treadmill exercise ECG testing,
pharmacologic testing and EPS. None of the subjects was on anti-arrhythmic or beta blocker
therapy during test performance. Three patients (IV- 1, IV-7 and IV-8) underwent only
echocardiogram and resting ECG. Epinephrine was given during 25min in an incremental,
escalating infusion protocol (0.025– 0.3 µg/kg/min), in order to assess the possibility of
LQTS and CPVT (15, 16). The proband’s sister (III- 4 in pedigree) and her children
undergoing EPS were also given isoproterenol (0.02 mg/min increased till reaching a 150%
increase in heart rate from baseline) during the EPS. Adenosine was given at escalating
doses of 6 mg till complete atrioventricular block was achieved (17), in order to assess the
possibility of LQTS. Flecainide was administered intravenously at a dose of 2 mg/kg/10min
in order to provide evidence for the possibility of Brugada syndrome (18).
In order to further investigate the findings of the short-long sequence during AF that resulted
in marked QT prolongation prior to VF onset in family member V-2 (Fig 1), we designed an
EPS protocol which could reproduce similar findings: 1. We delivered bursts (15–30sec) of
rapid right ventricular pacing at various rates (100/min, 150/min, 200/min) and measured the
first post-pacing beat QT interval following the burst delivery; 2. Similar QT measurements
were performed following short-long sequence of double right ventricular extrastimulation
(S2S3) delivered at two basic cycle lengths (6 beat basic drive S1S1 of 600 and 400 ms),
using electrical stimulus strength at double diastolic threshold. During basic pacing
S1S1=600msec, S1S2 was fixed at 300msec and S3 was initially introduced at
S2S3=950msec, reducing this interval progressively in 10msec decrements until S2S3
reached 300msec. During basic pacing S1S1=400msec, S1S2 was fixed at 250msec and S3
was introduced at S2S3=850msec, reducing this interval progressively in 10msec
decrements until S2S3 reached 250msec. The longest post-pacing QT and T (peak)-T (end)
interval measured was considered for analysis.
A group of six unrelated patients undergoing ablation of supraventricular tachycardia and
two members of another CPVT family with a R420Q RyR2 mutation were used as controls.
The EPS protocol for controls and family members was identical. The parents signed an
informed consent form before the EPS protocol was carried out.
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Genetic screening involved direct sequencing of genes, encoding sodium- potassium-
calcium-inward rectifying potassium- cardiac ion channels and RyR2 (Table 1).
RESULTS
Clinical and EP results
Four proband's children (including the 2 who exhibited aborted cardiac arrest), the proband's
sister (III-4 in pedigree; Fig 1) and 5 of her 8 children, underwent the various clinical
investigations. The non-invasive clinical tests were normal in the 10 patients evaluated, with
the exception of exercise-induced multifocal single PVCs and epinephrine-induced non-
sustained VT in the proband's sister (III-4 in pedigree; Fig 1).
EPS was performed in all 10 family members. Baseline heart rate and QT intervals were
normal in all patients (heart rate ranging from 62–100 beats/min and mean QTc of 414 ± 31
ms). No significant arrhythmias could be induced with either bursts of rapid ventricular
pacing or double extrastimulation protocol In five family members both rapid ventricular
pacing and double ventricular extrastimulation were followed by a marked increase in QT
and QTpeak-end only in the first post-pacing beat (Fig. 1- A and 4) (Table 2). In one patient
(IV- 6 in Fig.1) only the extrastimulation but not the rapid pacing protocol resulted in T
wave changes. All changes were consistently reproducible throughout the EPS. There were
no significant post-pacing changes in QT and QTpeak-end in the other family members, in the
two control patients of the other family carrying the R420Q - RYR2 mutation, and in the six
control patients undergoing the same EPS protocol.
At this stage, while awaiting the results of genetic testing (see below) and considering the
malignant family history of SCD, an ICD was prophylactically implanted to the proband's
two asymptomatic daughters aged 13 and 16 years (V-1 and V-3 in pedigree; Fig 1).
Genetic results
Genetic analysis revealed a heterozygous nucleotide substitution of T to G at cDNA position
12056 predicting a change from amino acid Methionine to Arginine at position 4109 of
RyR2 (M4109R) (NCBI Ref: NM_001035) (Fig. 5A) in family members III- 2, III-4, IV- 2,
IV- 3, IV- 6 and V- 2 and V-4 (Fig. 1- B). Another heterozygous nucleotide substitution of T
to C at cDNA position 3179 predicting a change from Isoleucine to Threonine at position
406 of RyR2 (I406T) (NCBI Ref: NM_001035) (Fig. 5B) was found in family members
III-1, V- 2, V-4 and V-5 (Fig. 1- B). Both mutations were found in a conserved region and
were absent in 200 normal controls, including 100 ethnically matched individuals. No
mutation was found in the other associated long QT genes (Table 1).
Correlation between electrophysiologic and genetic results
The six family members found to have the prominent post-pacing QT changes were all
carriers of the M4109R mutation (Figs. 1 A+B). Family members without the M4109R
RyR2 mutation did not show these changes.
Clinical course
Based on the genetic results, we decided to remove the ICD from the two family members
(V-1 and V-3) in whom it was implanted prophylactically. During a follow-up of 30 months
following the electrophysiological evaluation, the proband’s son (V-2 in pedigree; Fig 1)
had a few episodes of exercise-induced VT treated appropriately by his ICD. None of the
asymptomatic patients had exhibited a symptomatic arrhythmic event (except for the
proband's sister (III- 4 in pedigree), in whom one episode of asymptomatic non-sustained
VT was recorded at ICD interrogation 9 months later.
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After a thorough discussion with the proband's sister, it was decided to avoid ICD
implantation in her three children carrying the M4109R mutation and treat them with beta-
blockers and exercise limitation.
Following the report showing the ability of flecainide to abolish arrhythmias in CPVT
patients (19), the medication (2mg/kg administered over a 6-minute period) was tested in the
proband's sister (III-4 in pedigree). The marked post-pacing repolarization abnormalities
observed during baseline were abolished after drug administration (Fig. 6). Due to infection
of the ICD pocket with atypical mycobacteria, her ICD had to be removed. She was treated
with oral flecainide (150mg daily) till her ICD was re- implanted.
DISCUSSION
Main findings
In this report, we describe a family with a high incidence of SCD and no evidence of
structural heart disease or LQTS. As in typical forms of CPVT, the two cases of documented
VF in the proband's family occurred during emotional stress. Despite extensive clinical
evaluation there was no evident cause for the arrhythmic events. Following the observation
of transient marked QT prolongation preceding VF onset in one of the cardiac arrest
survivors, extensive EPS was performed in the family members. Marked prolongation of QT
and QTpeak- end after rapid ventricular pacing and/or after ventricular extrastimulation using
a short-long sequence, was found in the two patients who had aborted cardiac arrest and in
four asymptomatic family members. Genetic screening excluded a large number of
candidate genes known to be associated with inherited arrhythmogenic syndromes
(specifically LQTS) and eventually found two mutations in the RyR2 gene. While the
M4109R mutation segregated along all those who had post-pacing repolarization
abnormalities, the I406T variant was found in the proband's asymptomatic husband,
asymptomatic youngest child (III- 1 and V-5 in pedigree, Fig. 1) and their two children who
had VF at a young age. While the clinical association of the M4109R mutation with
arrhythmias in this family is clear, the role of I406T remains unclear. Potentially, the
combination of both mutations may cause a more severe phenotype, but careful inspection
of the family pedigree reveals that the unique presence of M4109R is also associated with a
severe phenotype (SCD at age 9 in family member III- 5). As M4109R and I406T were
found on separate alleles in this family and the mother (II- 6 in pedigree) was negative for
RyR2 mutations, it is more likely to assume that family member III-5, who died suddenly at
the age of 9, was a carrier of the M4109R mutation only (like his sisters) rather than I406T
mutation only. Family member III-1 and V-5, the only proven carriers of I406T mutation
alone are both asymptomatic (III-1 has also both a normal exercise testing and 24-hr ECG
recording).
Clinical correlation
Mutations in RyR2 are associated with CPVT (5). Emotional stress-induced SCD in the
presence of normal QRS width or morphology, normal QTc interval and normal
echocardiography in the affected family members, suggests a diagnosis of CPVT.
Surprisingly, exercise-induced ventricular arrhythmias, considered to be the hallmark of
CPVT, were not documented in our two young patients presenting with SCD as well as in
any of the other patients tested, except for one asymptomatic family member. However,
published series of CPVT patients have demonstrated that individuals may present with
SCD during adrenergic stress in the absence of exercise inducibility (5, 6). In the genetic era
one cannot totally rely on the diagnostic accuracy of exercise testing. In CPVT families, not
all RyR2 mutation carriers display exercise induced arrhythmias and indeed in most cases
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penetrance is not 100% (5, 6, 11). These studies and our study emphasize the importance of
RyR2 genetic testing.
Mechanism of QT prolongation
The cardiac RyR2 is located in the sarcoplasmic reticulum and is responsible for the release
of calcium into the cardiac myocyte cytosol during systole (13). The mechanisms by which
RyR2 mutations lead to life-threatening arrhythmias remain controversial. However, the
common pathway to all theories is that mutations cause a RyR2 "gain of function" leading to
diastolic Ca2+ leakage during diastole. Such a leak may lead to DADs giving rise to
triggered responses and VT/VF (20). Most RyR2 mutations cluster into three main regions:
the N-terminal, the central domain, and the C-terminal, including the calcium binding site
and the channel-forming transmembrane domains (5, 6, 12, 14). M4109R is not an exception
to these findings and is in fact located in the calcium binding site domain. Interestingly,
George et al. (14) found that mutations concentrated in this domain demonstrate more post-
activation channel instability than mutations in other domains. This instability results in
Ca2+ release dysfunction. Rapid pacing loads the myocytes with sodium resulting in
significant calcium loading during the pause via reverse-mode Na/Ca exchange. The RyR2
defect would most likely further promote calcium loading of the cells. The beat after the
pause would be expected to be associated with a particularly large calcium transient,
resulting in prolongation of the action potential duration (APD) and thus QT via forward-
mode electrogenenic Na/Ca exchange current.
Post-acceleration induced prolongation APD has been previously demonstrated in M cell
preparation isolated from the canine heart and pretreated with IKr blockers. Burashnikov et
al. (21) have provided evidence that this was mediated via calcium loading mechanism.
Thus the RYR2 defect in our family may operate via a similar mechanism.
Viitasalo M et al. (22) and others (4, 23) also have found that CPVT patients display
repolarization abnormalities manifesting as U waves. In contrast to these previous studies,
none of the RyR2 mutation carriers in our study displayed prominent T2 or U waves at rest.
The prominent repolarization changes were seen only after rapid pacing followed by a
pause. In addition, the changes observed are more consistent with APD prolongation
correlating with the giant T waves observed rather than with T2/ U waves (correlating with
DADs). Interestingly, Viskin et al. (24) have shown that a post-extrasystolic pause can lead
to augmentation of both T and U waves in patients with ventricular arrhythmias, with the
latter serving as a marker for ventricular arrhythmias.
Of note, after administration of adenosine in our patients pauses secondary to AV block and
bradycardia were not followed by significant QT prolongation.
The reason why those patients with R420Q -RyR2 did not display the post-pacing QT
prolongation is not clear. The change at position 420 is located in the N-terminal region and
it is possible that mutations in this locus manifest in a different way (albeit similar events of
SCD, several of them occurring at a young age). Another possibility is that these finding are
specific for the M4109R mutation.
Following flecainide administration in one gene mutation carrier patient, the post-pacing QT
interval prolongation reversed back to normal (Fig. 6). Recently, Watanabe et al. (19)
demonstrated that flecainide has the ability to reduce Ca2+ release from the sarcoplasmic
reticulum by inhibiting RyR2. Thus, the reduction in calcium overload under flecainide
during rapid pacing can theoretically prevent in a similar manner the post-pacing APD
prolongation.
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Study limitations
1. The role of I406T is unclear. There is a rare possibility that this mutation is responsible
for the occurrence of SCD in family members V-2 and V-4. However it is very unlikely to
assume there are two very lethal mutations coexisting in the same family. Furthermore, the
only two proven isolated I406T mutation carriers are asymptomatic while at least M4109R
by itself is responsible for the SCD of the proband and the polymorphic VT of her sister.
M4109R is also clearly associated with post pacing and pause QT prolongation. Therefore,
we assume that this mutation is the lethal mutation in the family. Further, functional studies
might be able to clarify the addition role of I406T.
2. The findings observed in this study are presently limited to the family described only. The
finding described may be specific for this RyR2 mutation. Further studies are required to
assess whether these T wave changes are present in other CPVT cases.
Conclusions
We report a new electrophysiologic marker that helped to identify RyR2 mutation carriers in
a CPVT family with a high incidence of SCD. To date, EPS was considered devoid of any
significant value in the diagnosis and clinical management of CPVT. Yet post-pacing QT
prolongation accurately identified all mutation carriers in our family. Further studies are
warranted to assess the value of this marker in identifying other RyR2 mutation carriers.
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Fig. 1.
A: Pedigree of family members. Shown in black are those members where EPS
demonstrates a post-pacing prolonged QT. B: Pedigree of genetic testing. All 6 family
members with a positive EPS were found to have a heterozygous missense mutation
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(M4109R) in RyR2. Two of them, presenting with aborted SCD, also had a second missense
mutation (I406T-RyR2). Four family members without RyR2 mutations did not
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Fig. 2.
Patient V-2 in pedigree; A: Initiation of AF leading to polymorphic VT and VF. VF
occurred after a marked QT prolongation following a short-long sequence during AF. B:
Magnification of the short-long sequence preceding the onset of VF.
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Fig. 3.
Rapid ventricular pacing from ICD lead in patient V-2 in pedigree. Notice the abnormal T
wave only in the first sinus beat following the pause.
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Fig. 4.
EPS in four children of patient III-4 (proband's sister); A: Normal T wave on the first sinus
beat following termination of rapid ventricular pacing in a non-M4109R-RyR2 carrier. B
and C: Abnormal T wave on the first sinus beat following rapid ventricular pacing in two
asymptomatic M4109R-RYR2 carriers (patients IV-2 and IV-4; respectively). D: Abnormal
T wave on a late ventricular paced beat (S3) following short-long sequence of double right
ventricular extrastimulation (S2S3) in another asymptomatic M4109R-RYR2 carrier (patient
IV-6 in pedigree).
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Fig. 5.
Electropherograms demonstrating: A: Insertion of T to G at position 4126 predicting a
substitution of Methionine for Arginine amino acid at position 4109 of RyR2 (M4109R); B:
Heterozygous nucleotide insertion of T to C at position 3179 predicting a substitution of
Isoleucine for Threonine amino acid at position 406 of RyR2 (I406T).
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Fig. 6.
Patient III-4; A: Marked QT prolongation on the first ventricular paced beat following rapid
ventricular pacing during control. B and C: After intravenous flecainide, both the first post-
pacing ventricular paced beat (B) and the first supraventricular escape beat (C) show a
normal QT.
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Table 1
Candidate genes screened in affected family members
Ion Channels Genes
Sodium channels SCN5A
SCN4B
RRAD
Potassium channels KCNH2
KCNQ1
KCNE1
KCNE2
KCNJ2
Calcium channels CACANA1C
CACNB2b
CACNA2D1
Ryanodine receptor RyR2
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